Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2023, titled "Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets".
Press Release Dec 15 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Darunavir Tablets in various strengths, along with tentative approval for additional strengths. The product will be manufactured at Zydus's facility in Ahmedabad, India, and the company has a significant number of approvals and filings with the USFDA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 14 2023
- Press Release Dec 11 2023
- Press Release Dec 06 2023
- Press Release Dec 01 2023
- Press Release Nov 10 2023
Later from Zydus Lifesciences
- Press Release Dec 16 2023
- Press Release Dec 22 2023
- Press Release Jan 17 2024
- Zydus Lifesciences Limited Press Release Jan 19 2024
- Press Release Jan 25 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences